CD8A and neoplasm: We observed that mice vaccinated with E7 peptide-based vaccine in combination with PADRE peptide and poly(I:C) generate significantly higher frequency of E7-specific CD8+ T cells as well as significant therapeutic anti-tumor effects against TC-1 tumors.